Abstract
Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The average lifetime risk of developing Alzheimer disease is 10-12%. This risk at least doubles with the presence of a first-degree relative with the disorder. Despite its limited utility, patients express concern over their risk and, in some instances, request testing. Furthermore, research has demonstrated that testing individuals for apolipoprotein E can be valuable and safe in certain contexts. However, because of the complicated genetic nature of the disorder, few clinicians are prepared to address the genetic risks of Alzheimer disease with their patients. Given the increased awareness in family history thanks to family history campaigns, the increasing incidence of Alzheimer disease, and the availability of direct to consumer testing, patient requests for information is increasing. This practice guideline provides clinicians with a framework for assessing their patients genetic risk for Alzheimer disease, identifying which individuals may benefit from genetic testing, and providing the key elements of genetic counseling for AD.
| Original language | English |
|---|---|
| Pages (from-to) | 597-605 |
| Number of pages | 9 |
| Journal | Genetics in Medicine |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2011 |
| Externally published | Yes |
Fingerprint
Keywords
- Alzheimer disease
- dementia
- genetic counseling
- genetic testing
- guideline
ASJC Scopus subject areas
- Genetics(clinical)
Cite this
Genetic counseling and testing for Alzheimer disease : Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. / Goldman, Jill S.; Hahn, Susan E.; Catania, Jennifer Williamson; Larusse-Eckert, Susan; Butson, Melissa Barber; Rumbaugh, Malia; Strecker, Michelle N.; Roberts, J. Scott; Burke, Wylie; Mayeux, Richard; Bird, Thomas.
In: Genetics in Medicine, Vol. 13, No. 6, 01.06.2011, p. 597-605.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Genetic counseling and testing for Alzheimer disease
T2 - Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors
AU - Goldman, Jill S.
AU - Hahn, Susan E.
AU - Catania, Jennifer Williamson
AU - Larusse-Eckert, Susan
AU - Butson, Melissa Barber
AU - Rumbaugh, Malia
AU - Strecker, Michelle N.
AU - Roberts, J. Scott
AU - Burke, Wylie
AU - Mayeux, Richard
AU - Bird, Thomas
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The average lifetime risk of developing Alzheimer disease is 10-12%. This risk at least doubles with the presence of a first-degree relative with the disorder. Despite its limited utility, patients express concern over their risk and, in some instances, request testing. Furthermore, research has demonstrated that testing individuals for apolipoprotein E can be valuable and safe in certain contexts. However, because of the complicated genetic nature of the disorder, few clinicians are prepared to address the genetic risks of Alzheimer disease with their patients. Given the increased awareness in family history thanks to family history campaigns, the increasing incidence of Alzheimer disease, and the availability of direct to consumer testing, patient requests for information is increasing. This practice guideline provides clinicians with a framework for assessing their patients genetic risk for Alzheimer disease, identifying which individuals may benefit from genetic testing, and providing the key elements of genetic counseling for AD.
AB - Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The average lifetime risk of developing Alzheimer disease is 10-12%. This risk at least doubles with the presence of a first-degree relative with the disorder. Despite its limited utility, patients express concern over their risk and, in some instances, request testing. Furthermore, research has demonstrated that testing individuals for apolipoprotein E can be valuable and safe in certain contexts. However, because of the complicated genetic nature of the disorder, few clinicians are prepared to address the genetic risks of Alzheimer disease with their patients. Given the increased awareness in family history thanks to family history campaigns, the increasing incidence of Alzheimer disease, and the availability of direct to consumer testing, patient requests for information is increasing. This practice guideline provides clinicians with a framework for assessing their patients genetic risk for Alzheimer disease, identifying which individuals may benefit from genetic testing, and providing the key elements of genetic counseling for AD.
KW - Alzheimer disease
KW - dementia
KW - genetic counseling
KW - genetic testing
KW - guideline
UR - http://www.scopus.com/inward/record.url?scp=79959193198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959193198&partnerID=8YFLogxK
U2 - 10.1097/GIM.0b013e31821d69b8
DO - 10.1097/GIM.0b013e31821d69b8
M3 - Article
C2 - 21577118
AN - SCOPUS:79959193198
VL - 13
SP - 597
EP - 605
JO - Genetics in Medicine
JF - Genetics in Medicine
SN - 1098-3600
IS - 6
ER -